Changeflow GovPing Healthcare & Life Sciences PROMPT Trial Tests Thoracoscopy for Pleural Inf...
Routine Notice Added Draft

PROMPT Trial Tests Thoracoscopy for Pleural Infection

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

The PROMPT trial (NCT07550530) is a randomized controlled study evaluating whether early Medical Thoracoscopy improves outcomes compared to standard-of-care treatment for pleural infection. Approximately 170 patients at multiple hospital sites will be enrolled and randomly assigned to either the thoracoscopy intervention or standard care. The primary endpoint is the rate of additional procedures (drain or surgery) required within 30 days, with secondary endpoints assessing recovery speed and complications. The trial is registered on ClinicalTrials.gov under NIH oversight.

“About 170 patients in several hospitals will be randomly assigned to one of the two treatments, and researchers will see which approach results in fewer additional procedures-such as another drain or surgery-within 30 days, as well as how quickly people recover and whether they experience any complications.”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.

What changed

The PROMPT trial registers a new randomized controlled study on ClinicalTrials.gov, investigating the comparative effectiveness of Medical Thoracoscopy versus standard treatment for pleural infection. The protocol specifies enrollment of approximately 170 patients at multiple hospital sites, with randomization to either the thoracoscopy intervention or standard of care.

For healthcare providers and clinical investigators, this registry entry signals an upcoming comparative effectiveness study in pleural infection management. Sites considering participation or seeking to align local protocols with emerging evidence may wish to monitor the trial's outcomes. The study's 30-day additional-procedure endpoint may inform future clinical guidelines for managing complicated parapneumonic effusion and empyema.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Role of Medical Thoracoscopy in Pleural Infection (PROMPT Trial)

N/A NCT07550530 Kind: NA Apr 24, 2026

Abstract

The PROMPT study is testing whether an early keyhole procedure called Medical Thoracoscopy, which lets doctors look inside the chest and remove infected fluid, works better than current standard treatment (medicines to break up thick fluid) for people with pleural infection. About 170 patients in several hospitals will be randomly assigned to one of the two treatments, and researchers will see which approach results in fewer additional procedures-such as another drain or surgery-within 30 days, as well as how quickly people recover and whether they experience any complications. Everyone in the study receives high-quality care, and the results will help doctors better understand which treatment gives patients the best chance of recovering quickly and safely

Conditions: Pleural Infection, Pleural Infections, Pleural Infections and Inflammations

Interventions: medical thoracoscopy, Standard of Care

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 24th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Draft
Change scope
Minor

Who this affects

Applies to
Clinical investigators Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial recruitment Medical procedure evaluation Pleural infection treatment
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Medical Devices Pharmaceuticals

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!